Lba01-13 future Projections of Symptomatic Pediatric Nephrolithiasis in the United States - A Time Series Analysis

Abstract

demonstrated short duration of systemic uptake. A dose response was observed. Responder analysis evaluating hematuria, and symptoms noted complete response in 3 subjects, partial response in 7 subjects and no response in 3 subjects. (NR["no response", PR["partial response", CR["complete response") (normalized rank, 0 to 9) (Figure 1).CONCLUSIONS: The results of the Phase 2a study demonstrated safety and a signal of efficacy with dose response of LP-10 for the treatment of refractory moderate to severe HC. This is the first successfully completed trial for cancer survivors with HC and more research is needed to develop a drug treatment for hemorrhagic cystitis, a disease with great unmet need.